Dr. Reddy Reports the Completion of the P-I Study of DRL_TC, a Proposed Biosimilar of Tocilizumab for Rheumatoid Arthritis
Shots:
- The P-I study evaluating PK & PD of proposed tocilizumab biosimilar DRL_TC via the IV route vs US sourced Actemra (tocilizumab) and EU sourced RoActemra (tocilizumab)
- The trial met its 1EPs & 2EPs and showed PK equivalence and similarity in PD parameters, safety, and immunogenicity b/w proposed biosimilar candidate (DRL_TC) and tocilizumab
- In Dec 2022, the company also highlighted the successful completion of the P-I study of DRL_TC via the SC route. Additionally, the company initiates the P-III study to evaluate the efficacy, safety, tolerability, and immunogenicity of DRL_TC in patients with mod. to sev. active rheumatoid arthritis
Ref: Businesswire | Image: Dr. Reddy
Related News:- Junshi Biosciences Collaborated with Dr. Reddy’s to Develop and Commercialize Toripalimab for the Treatment of Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
